Table 1. Demographic, clinical, and... | American Society of Hematology

Table 1.

Demographic, clinical, and tumor characteristics

Clinical characteristic	Total cohort		HCMBL		CLL
	(N = 1226)		(n = 371)		(n = 855)
	n	%	n	%	n	%
Sex
Female	327	31.90	114	36.80	213	29.30
Male	699	68.10	196	63.20	503	70.30
Age, median (range)	63 (27-95)		67 (42-95)		61 (27-94)
Race
Caucasian	1089	88.80	364	98.15	725	84.80
Other	137	11.20	7	1.20	130	15.20
Rai stage risk group
Rai 0	831	68.80	371	100	460	55.00
Rai I-II	326	27.00	-	-	326	38.90
Rai III-IV	51	4.20	-	-	51	6.10
Missing	18				18
Fluorescence in situ hybridization at diagnosis∗
13q deletion	587	57.50	162	54.60	425	58.90
Trisomy 12	164	16.10	49	16.40	115	15.90
11q deletion	103	10.10	15	5.00	88	12.20
17p deletion	55	5.40	8	2.60	47	6.50
Normal	233	22.70	85	28.10	148	20.50
Other	15	1.50	3	1.00	12	1.70
Missing	200		68		132
*TP53*
Mutated	124	10.10	30	8.10	124	10.10
Unmutated	921	89.80	287	92.60	634	88.50
Missing	0		0		0
IgHV mutation status
Mutated	611	55.90	221	75.40	390	48.70
Unmutated	483	44.10	72	24.60	411	51.30
Missing	132		78		54
β2 microglobulin
≤3.5 mg/L	867	81.60	278	89.70	589	78.30
>3.5 mg/L	195	18.40	32	10.30	163	21.70
Missing	164		61		103
Median (range)	2.4 (0.2-121.5)		2.1 (1.0-21.5)		2.4 (0.2-16.2)
CLL-IPI
Low risk (0-1)	447	42.78	179	60.70	268	35.73
Intermediate risk (2-3)	313	29.95	70	23.70	243	32.40
High/very high risk (4-10)	285	27.27	46	15.60	239	31.87
Missing	181		76		105
B-cell count, ×10⁹/L
Median (range)	6.7 (0.2-394.5)		2.9 (0.5-4.9)		11.8 (0.2-394.5)
Missing	164		48		116

Clinical characteristic	Total cohort		HCMBL		CLL
	(N = 1226)		(n = 371)		(n = 855)
	n	%	n	%	n	%
Sex
Female	327	31.90	114	36.80	213	29.30
Male	699	68.10	196	63.20	503	70.30
Age, median (range)	63 (27-95)		67 (42-95)		61 (27-94)
Race
Caucasian	1089	88.80	364	98.15	725	84.80
Other	137	11.20	7	1.20	130	15.20
Rai stage risk group
Rai 0	831	68.80	371	100	460	55.00
Rai I-II	326	27.00	-	-	326	38.90
Rai III-IV	51	4.20	-	-	51	6.10
Missing	18				18
Fluorescence in situ hybridization at diagnosis∗
13q deletion	587	57.50	162	54.60	425	58.90
Trisomy 12	164	16.10	49	16.40	115	15.90
11q deletion	103	10.10	15	5.00	88	12.20
17p deletion	55	5.40	8	2.60	47	6.50
Normal	233	22.70	85	28.10	148	20.50
Other	15	1.50	3	1.00	12	1.70
Missing	200		68		132
*TP53*
Mutated	124	10.10	30	8.10	124	10.10
Unmutated	921	89.80	287	92.60	634	88.50
Missing	0		0		0
IgHV mutation status
Mutated	611	55.90	221	75.40	390	48.70
Unmutated	483	44.10	72	24.60	411	51.30
Missing	132		78		54
β2 microglobulin
≤3.5 mg/L	867	81.60	278	89.70	589	78.30
>3.5 mg/L	195	18.40	32	10.30	163	21.70
Missing	164		61		103
Median (range)	2.4 (0.2-121.5)		2.1 (1.0-21.5)		2.4 (0.2-16.2)
CLL-IPI
Low risk (0-1)	447	42.78	179	60.70	268	35.73
Intermediate risk (2-3)	313	29.95	70	23.70	243	32.40
High/very high risk (4-10)	285	27.27	46	15.60	239	31.87
Missing	181		76		105
B-cell count, ×10⁹/L
Median (range)	6.7 (0.2-394.5)		2.9 (0.5-4.9)		11.8 (0.2-394.5)
Missing	164		48		116

Individuals can have >1.